Treatment of chronic hepatitis C in patients with HIV/HCV coinfection

Table 1 Sustained virological response rate in human immunodeficiency virus/hepatitis C virus coinfected patients naïve for anti-hepatitis C virus treatment

	Ref.	SVR rate in therapy-naive patients
		Genotype 1	Genotype 2	Genotype 3	Genotype 4
Peg-IFN plus ribavirin	[85]	35.6% in 191 patients	72.4% in 152 patients		32.6% in 46 patients
Peg-IFN plus ribavirin + boceprevir	[32]	60.7% in 61 patients	-	-	-
Peg-IFN plus ribavirin + telaprevir	[51]	74% in 38 patients	-	-	-
Peg-IFN plus ribavirin + sofosbuvir	[44]	91% in 23 patients
Peg-IFN plus ribavirin + simeprevir	[55]	79.2% in 52 patients	-	-	-
Peg-IFN plus ribavirin + faldaprevir	[59]	73.7% in 227 patients1	-	-	-
Sofosbuvir plus ribavirin	[60]	76% in 114 patients2	88% in 26 patients3	67% in 42 patients3	-
Sofosbuvir plus ribavirin	[62]	84% in 112 patients	90% in 19 patients	91% in 57 patients	84% in 31 patients
Sofosbuvir plus ledipasvir	[63]	100% in 13 patients	-	-	-
Paritaprevir-r/ombitasvir + dasabuvir + ribavirin	[65]	93.50% in 31 patients	-	-	-

¹Therapy-naïve or relapser patients;

²For 24 wk;

³For 12 wk. SVR: Sustained virological response; Peg-IFN: Pegylated interferon alfa.